Skip to main content

Table 6 Incidence reduction with quadrivalent and nonavalent vaccination at steady-state

From: Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria

 

4-valent vaccination

9-valent vaccination

Female

 Cervical incidence

−75 %

−92 %

 Cervical death

−74 %

−91 %

 Genital warts

−85 %

−85 %

 CIN 1

−74 %

−96 %

 CIN 2+

−76 %

−96 %

 Vaginal incidence

−91 %

−91 %

 Vulvar incidence

−92 %

−92 %

 Anal incidence

−80 %

−83 %

 Anal death

−78 %

−81 %

 H & N incidence

−81 %

−81 %

Male

 Anal incidence

−76 %

−78 %

 Anal death

−74 %

−76 %

 Genital warts

−79 %

−79 %

 Penile incidence

−54 %

−55 %

 H & N incidence

−77 %

−77 %